Abstract
Aim: to assess the influence of endothelin receptor antagonist Bosentan on catecholamines levels in pts with idiopathic pulmonary arterial hypertension (IPAH).Methods: In the single-center comparative study we included 35 pts aged 35,2±9,6ys with IPAH confirmed by RHC(WHO Functional Class (FC) II-IV)without systemic inflammation signs.On top of stable therapy with anticoagulants,diuretics,glycosides,calcium antagonists for at least 3 months,Bosentan therapy was started 62,5 mg twice daily for 4 wks.At wk4 the pts were randomized 1:1 by the envelope method to bosentan 125 or 250 mg/day.At baseline, at wk3 and wk12 visits the pts underwent the clinical and lab assessment,including catecholamines(HPLC).Results: At baseline IPAH groups were comparable by age,sex,disease duration,hemodynamic parameters.In both groups the levels of norepinephrine were significantly higher than normal values(139,9±1,2).Otherwise the epinephrine levels were decreased as compared with controls(69,4±1,2).
Conclusion: In IPAH pts Bosentan therapy influenced on catecholanines levels by significant reduction of initially increased norepinephrine levels.This effect was more pronounced in Pts treated with Bosentan 125mg daily.
- © 2012 ERS